Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.54 |
| ▸ | DRD4 | P21917 | 2/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1833770 | 0.87 | POLB (0.62) | KMT2AL3MBTL1POLBSLC29A1ATM | |
| SCHEMBL14430686 | 0.87 | DRD4 (0.70) | SMYD2MAPTDRD2DRD4 | |
| SCHEMBL5476524 | 0.85 | SMYD2 (0.62) | SMYD2KMT2AMEN1HPGDL3MBTL1 | |
| SCHEMBL5482155 | 0.85 | SMYD2 (0.68) | SMYD2KMT2AMEN1HPGDL3MBTL1 | |
| SCHEMBL14372313 | 0.84 | HTR7 (0.57) | KMT2AMEN1POLBMAPTDRD2 | |
| SCHEMBL5477335 | 0.83 | DRD4 (0.66) | SMYD2MAPTDRD2DRD4 | |
| SCHEMBL5474859 | 0.82 | MEN1 (0.61) | SMYD2KMT2AMEN1HPGDL3MBTL1 | |
| SCHEMBL16964662 | 0.82 | MAPT (0.62) | SMYD2KMT2AMEN1HPGDL3MBTL1 | |
| SCHEMBL5480942 | 0.82 | L3MBTL1 (0.61) | SMYD2KMT2AMEN1HPGDL3MBTL1 | |
| SCHEMBL5479770 | 0.82 | SMYD2 (0.61) | SMYD2KMT2AMEN1HPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191358-A1 | Novel piperidine derivative for the treatment of depression | GRIN2C, TPH2, HTR5A | SMYD2 805/4885KMT2A 234/4885MEN1 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.